Cancers · 2020 · 28 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyMolecular OncologyCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyCytotoxic T Lymphocyte ResponsesHybridoma TechnologyLymphocyte ActivationT Cell ActivationAnaplastic Lymphoma Kinase InhibitionB7 Family Immunoregulatory LigandsCytokine Secretion RegulationCytotoxicity AssaysT Cell CytotoxicityT-cell Malignancy Therapy
) anaplastic large cell lymphoma (ALCL), which is the most common subtype of T cell lymphoma. In this study, we observed overexpression of B7-H3 in ALCL cell lines derived from clinical samples and differential expression of B7-H3 in an ALK-induced T cell transformation model. A B7-H3-redirected CAR based on scFv from mAb 376.96 was developed. B7-H3 CAR-T cells showed strong cytotoxicity and cytokine secretion against target ALCL cells (SUP-M2, SU-DHL-1, and Karpas 299) in vitro. Furthermore, the B7-H3 CAR-T cells exhibited proliferative capacity and a memory phenotype upon repeated antigen stimulation. We demonstrated that B7-H3 CAR-T cells could promptly eradicate ALCL in murine xenografts. Taken together, B7-H3 is a novel and promising target in ALCLs and B7-H3 CAR-T may be a viable treatment option for ALCL.
25
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Daniel R. Rhodes, Jianjun Yu, K. Shanker et al. · Neoplasia · 2004 · 3.7K citations · Full text
H Stein, DY Mason, Johannes Gerdes et al. · Blood · 1985 · 1.8K citations · Full text
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Andrei I. Chapoval, Jian Ni, Julie S. Lau et al. · Nature Immunology · 2001 · 1K citations